Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.3000 |
Strike | 7.50 |
Expiry date | 2024-09-20 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 100 |
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Adaptimmune Therapeutics ( NASDAQ:ADAP ) Full Year 2023 Results Key Financial Results Revenue: US$60.3m (up 122% from...
Key Financial Highlights and Business Updates